Halozyme Therapeutics Inc (HALO)
Debt-to-assets ratio
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-term debt | US$ in thousands | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Total assets | US$ in thousands | 2,063,480 | 2,118,030 | 1,969,450 | 1,841,530 | 1,733,270 | 1,892,660 | 1,810,440 | 1,699,450 | 1,841,510 | 1,864,540 | 1,781,390 | 1,162,250 | 1,104,430 | 1,185,420 | 1,025,860 | 966,582 | 579,924 | 524,029 | 526,997 | 492,353 |
| Debt-to-assets ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
December 31, 2024 calculation
Debt-to-assets ratio = Long-term debt ÷ Total assets
= $—K ÷ $2,063,480K
= 0.00
Halozyme Therapeutics Inc has consistently maintained a debt-to-assets ratio of 0.00 across all reported quarters from March 31, 2020, to December 31, 2024. This indicates that the company does not have any long-term debt obligations relative to its total assets during this period. A debt-to-assets ratio of 0.00 suggests that the company is financing its operations primarily through equity rather than debt. This may signify a strong financial position and a lower risk of financial distress resulting from the burden of debt. However, it's important to note that a zero debt-to-assets ratio may also indicate missed opportunities for leveraging debt to potentially enhance returns. Overall, the consistent trend of a zero debt-to-assets ratio for Halozyme Therapeutics Inc reflects a conservative approach to capital structure and financial management.
Peer comparison
Dec 31, 2024